BOM:500660 (India)
Â
Shs Dematerialised
₹
2,494.2
-56.9 (-2.23%)
Jul 23
Business Description
GlaxoSmithKline Pharmaceuticals Ltd
ISIN : INE159A01016
Share Class Description:
BOM:500660: Shs DematerialisedTotal Employee Number:
3,103Compare
Compare
Traded in other countries / regions
500660.India IPO Date
1991-03-01Description
GlaxoSmithKline Pharmaceuticals Ltd is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals. It is healthcare organisation focused on uniting science, technology and talent to get ahead of disease. The company's product portfolio comprises a broad range of General Medicines which includes anti-infectives, pain management, vitamins, minerals, nutritionals, hormones, dermatologicals, vaccines for both children and adults, and specialty medicines for respiratory and oncology. Its focused brands are Augmentin, Ceftum, Flutivate, T-bat, Betnovate, Neosporin, Tenovate, Physiogel, Calpol and Calpol T. The company has single reportable segment. The company has presence in India, and also Outside India. It generates majority of revenue from India.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 82.84 | |||||
Equity-to-Asset | 0.52 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | 0.02 | |||||
Interest Coverage | 455.22 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 15.05 | |||||
Beneish M-Score | -2.46 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 5.7 | |||||
3-Year EBITDA Growth Rate | 17.7 | |||||
3-Year EPS without NRI Growth Rate | 18.7 | |||||
3-Year FCF Growth Rate | 24.4 | |||||
3-Year Book Growth Rate | 9.2 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 52.91 | |||||
9-Day RSI | 58.14 | |||||
14-Day RSI | 59.33 | |||||
3-1 Month Momentum % | -3.75 | |||||
6-1 Month Momentum % | 3.74 | |||||
12-1 Month Momentum % | -23.4 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.03 | |||||
Quick Ratio | 1.77 | |||||
Cash Ratio | 1.55 | |||||
Days Inventory | 132.85 | |||||
Days Sales Outstanding | 28.61 | |||||
Days Payable | 158.32 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 2.29 | |||||
Dividend Payout Ratio | 0.7 | |||||
3-Year Dividend Growth Rate | 11.9 | |||||
Forward Dividend Yield % | 2.29 | |||||
5-Year Yield-on-Cost % | 3.93 | |||||
Shareholder Yield % | 2.27 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 64.65 | |||||
Operating Margin % | 32.52 | |||||
Net Margin % | 27.11 | |||||
EBITDA Margin % | 38.6 | |||||
FCF Margin % | 22.19 | |||||
OCF Margin % | 23.64 | |||||
ROE % | 52.44 | |||||
ROA % | 25.69 | |||||
ROIC % | 74.77 | |||||
3-Year ROIIC % | -633.77 | |||||
ROC (Joel Greenblatt) % | 475.39 | |||||
ROCE % | 62.71 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 40.79 | |||||
Forward PE Ratio | 36.12 | |||||
PE Ratio without NRI | 41.48 | |||||
Shiller PE Ratio | 51.7 | |||||
Price-to-Owner-Earnings | 42.62 | |||||
PEG Ratio | 2.07 | |||||
PS Ratio | 11.06 | |||||
PB Ratio | 18.63 | |||||
Price-to-Tangible-Book | 18.69 | |||||
Price-to-Free-Cash-Flow | 49.81 | |||||
Price-to-Operating-Cash-Flow | 46.77 | |||||
EV-to-EBIT | 28.07 | |||||
EV-to-EBITDA | 26.81 | |||||
EV-to-Revenue | 10.35 | |||||
EV-to-FCF | 45.83 | |||||
Price-to-GF-Value | 0.95 | |||||
Price-to-Projected-FCF | 3.83 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.27 | |||||
Price-to-Graham-Number | 5.87 | |||||
| Price-to-Net-Current-Asset-Value | 27.25 | |||||
| Price-to-Net-Cash | 60.38 | |||||
Earnings Yield (Greenblatt) % | 3.55 | |||||
FCF Yield % | 1.99 | |||||
Forward Rate of Return (Yacktman) % | 21.77 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
GlaxoSmithKline Pharmaceuticals Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 38,216.7 | ||
| EPS (TTM) (₹) | 61.15 | ||
| Beta | 0.7009 | ||
| 3-Year Sharpe Ratio | 0.49 | ||
| 3-Year Sortino Ratio | 0.93 | ||
| Volatility % | 23.03 | ||
| 14-Day RSI | 59.33 | ||
| 14-Day ATR (₹) | 64.332574 | ||
| 20-Day SMA (₹) | 2444.65 | ||
| 12-1 Month Momentum % | -23.4 | ||
| 52-Week Range (₹) | 2088 - 3217.1 | ||
| Shares Outstanding (Mil) | 169.41 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
GlaxoSmithKline Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
GlaxoSmithKline Pharmaceuticals Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| INR 57.000000 Cash Dividend | 2026-05-29 | 2,301.05 (+0.52%) | ||
| INR 42.000000 Cash Dividend | 2025-05-30 | 3,269.05 (-2.39%) | ||
| INR 12.000000 Cash Dividend | 2024-11-07 | 2,632.20 (+1.40%) | ||
| 2:1 Stock Split | 2018-09-11 | 1,793.90 (+2.10%) |
Show
Entries
GlaxoSmithKline Pharmaceuticals Ltd Frequently Asked Questions
What is GlaxoSmithKline Pharmaceuticals Ltd(BOM:500660)'s stock price today?
The current price of BOM:500660 is ₹2494.20. The 52 week high of BOM:500660 is ₹3217.10 and 52 week low is ₹2088.00.
When is next earnings date of GlaxoSmithKline Pharmaceuticals Ltd(BOM:500660)?
The next earnings date of GlaxoSmithKline Pharmaceuticals Ltd(BOM:500660) is .
Does GlaxoSmithKline Pharmaceuticals Ltd(BOM:500660) pay dividends? If so, how much?
The Dividend Yield %  of GlaxoSmithKline Pharmaceuticals Ltd(BOM:500660) is 2.29% (As of Today), Highest Dividend Payout Ratio of GlaxoSmithKline Pharmaceuticals Ltd(BOM:500660) was 1.38. The lowest was 0.59. And the median was 0.75. The  Forward Dividend Yield % of GlaxoSmithKline Pharmaceuticals Ltd(BOM:500660) is 2.29%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on GlaxoSmithKline Pharmaceuticals Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers